Compliance with pharmacotherapy and direct healthcare costs in patients with parkinson's disease: A retrospective claims database analysis

Applied Health Economics and Health Policy

Volumn 11, Issue 4, 2013, Pages 395-406

  Richy, Florent F ^a,b   Pietri, Guilhem ^c   Moran, Kimberly A ^a   Senior, Emmanuelle ^a   Makaroff, Lydia E ^a  

^a UCB PHARMA   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c Heron Evidence Development Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; BENZATROPINE; BIPERIDEN; BROMOCRIPTINE; CABERGOLINE; CARBIDOPA PLUS ENTACAPONE PLUS LEVODOPA; ENTACAPONE; LEVODOPA; PERGOLIDE; PRAMIPEXOLE; PROCYCLIDINE; PROFENAMINE; RASAGILINE; ROPINIROLE; SELEGILINE; TOLCAPONE; TRIHEXYPHENIDYL;

ADULT; AGED; ARTICLE; CHILD; DEPRESSION; DRUG COST; EMERGENCY WARD; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; HEALTH CARE COST; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; MEDICAL FEE; OUTPATIENT CARE; PARKINSON DISEASE; PATIENT COMPLIANCE; PRESCRIPTION; RETROSPECTIVE STUDY; SCHOOL CHILD;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CONFIDENCE INTERVALS; DATABASES, FACTUAL; DRUG THERAPY; FEMALE; GUIDELINE ADHERENCE; HUMANS; MALE; MANAGED CARE PROGRAMS; MIDDLE AGED; ODDS RATIO; PARKINSON DISEASE; PRACTICE GUIDELINES AS TOPIC; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84880882795     PISSN: 11755652     EISSN: 11791896     Source Type: Journal    
DOI: 10.1007/s40258-013-0033-1     Document Type: Article

References (43)

1. de Rijk MC, Launer LJ, Berger K, Breteler MM, Dartigues JF, Baldereschi M, et al. Prevalence of Parkinson's disease in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology. 2000;54(11 Suppl 5):S21-3.
2. Canadian Neurological Sciences Federation. Canadian guidelines on Parkinson's disease. Can J Neurol Sci 2012;39(Suppl 4):S1-30.
3. Olanow CW, Stern MB, Sethi K. The scientific and clinical basis for the treatment of Parkinson disease (2009). Neurology. 2009;72(21 Suppl 4):S1-136.
4. Lewitt PA. Levodopa for the treatment of Parkinson's disease. N Engl J Med. 2008;359(23):2468-76.
5. Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology. 2007;68(5):384-6. (Pubitemid 46184217)
6. Pinder RM. Drugs for Parkinson's disease: levodopa is still the gold standard. Neuropsychiatr Dis Treat. 2008;4(1):i-ii. (Pubitemid 351460973)
7. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med. 2000;342(20):1484-91. (Pubitemid 30318272)
8. NICE. Parkinson's disease: diagnosis and management in primary and secondary care (Internet). 2011. http://www.nice.org.uk/CG035. Cited 9 Jan 2012.
9. Miyasaki JM, Martin W, Suchowersky O, Weiner W, Lang A. Initiation of treatment of Parkinson's disease (Internet). 2006. http://www.aan.com/ professionals/practice/guidelines/pda/Treatment-PD.pdf. Cited 4 Apr 2012.
10. Schapira AH. Treatment options in the modern management of Parkinson disease. Arch Neurol. 2007;64(8):1083-8. (Pubitemid 47258065)
11. Pahwa R, Factor SA, Lyons KE, Ondo WG, Gronseth G, Bronte-Stewart H, et al. Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006;66(7):983-95. (Pubitemid 44044780)
12. Horstink M, Tolosa E, Bonuccelli U, Deuschl G, Friedman A, Kanovsky P, et al. Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I: early (uncomplicated) Parkinson's disease. Eur J Neurol. 2006;13(11):1170-85. (Pubitemid 44581464)
13. Huse DM, Schulman K, Orsini L, Castelli-Haley J, Kennedy S, Lenhart G. Burden of illness in Parkinson's disease. Mov Disord. 2005;20(11):1449-54. (Pubitemid 43072653)
14. Grosset KA, Bone I, Grosset DG. Suboptimal medication adherence in Parkinson's disease. Mov Disord. 2005;20(11):1502-7. (Pubitemid 43072661)
15. Leopold NA, Polansky M, Hurka MR. Drug adherence in Parkinson's disease. Mov Disord. 2004;19(5):513-7.
16. Tarrants ML, Denarie MF, Castelli-Haley J, Millard J, Zhang D. Drug therapies for Parkinson's disease: a database analysis of patient compliance and persistence. Am J Geriatr Pharmacother. 2010;8(4):374-83.
17. Grosset KA, Bone I, Reid JL, Grosset D. Measuring therapy adherence in Parkinson's disease: a comparison of methods. J Neurol Neurosurg Psychiatry. 2006;77(2):249-51. (Pubitemid 43220854)
18. Hughes DA, Bagust A, Haycox A, Walley T. Accounting for noncompliance in pharmacoeconomic evaluations. Pharmacoeconomics. 2001;19(12):1185-97. (Pubitemid 34074782)
19. Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2008;(2):CD000011.
20. Sackett DL, Haynes RB, Gibson ES, Taylor DW, Roberts RS, Johnson AL. Patient compliance with antihypertensive regimens. Patient Couns Health Educ. 1978;1(1):18-21. (Pubitemid 9071898)
21. Grosset D. Therapy adherence issues in Parkinson's disease. J Neurol Sci. 2010;289(1-2):115-8.
22. Grosset D, Antonini A, Canesi M, Pezzoli G, Lees A, Shaw K, et al. Adherence to antiparkinson medication in a multicenter European study. Mov Disord. 2009;24(6):826-32.
23. O'Brien JA, Ward A, Michels SL, Spyridon T, Brandt N. Economic burden associated with Parkinson disease. Drug Benefit Trends. 2009;21(6):179-90.
24. PharMetrics. PharMetrics database (Internet). 2010. http://www.imshealth. com/portal/site/ims/menuitem.d248e29c86589c9c30e81c033208c22a/?vgnextoid= d6952a2e23264310VgnVCM100000ed152ca2RCRD&vgnextchannel= c03c90916e442310VgnVCM100000ed152ca2RCRD. Cited 16 Aug 2010.
25. Makaroff L, Gunn A, Gervasoni C, Richy F. Gastrointestinal disorders in Parkinson's disease: prevalence and health outcomes in a US claims database. J Parkinsons Dis. 2011;1(1):65-74.
26. Davis KL, Edin HM, Allen JK. Prevalence and cost of medication nonadherence in Parkinson's disease: evidence from administrative claims data. Mov Disord. 2010;25(4):474-80.
27. Chen JJ. Parkinson's disease: health-related quality of life, economic cost, and implications of early treatment. Am J Manag Care. 2010;16 Suppl Implications:S87-93.
28. Berger BA. Assessing and interviewing patients for meaningful behavioral change: part 1. Case Manag. 2004;15(5):46-50. (Pubitemid 39286813)
29. Bond WS, Hussar DA. Detection methods and strategies for improving medication compliance. Am J Hosp Pharm. 1991;48(9):1978-88.
30. McKenney JM, Munroe WP, Wright JT Jr. Impact of an electronic medication compliance aid on long-term blood pressure control. J Clin Pharmacol. 1992;32(3):277-83.
31. Ley P, Jain VK, Skilbeck CE. A method for decreasing patients' medication errors. Psychol Med. 1976;6(4):599-601.
32. Galloway R, McGuire J. Determinants of compliance with iron supplementation: supplies, side effects, or psychology? Soc Sci Med. 1994;39(3):381-90. (Pubitemid 24191618)
33. Rohsenow DJ. What place does naltrexone have in the treatment of alcoholism? CNS Drugs. 2004;18(9):547-60. (Pubitemid 38951778)
34. Garfield FB, Caro JJ. Compliance and hypertension. Curr Hypertens Rep. 1999;1(6):502-6.
35. Steinmetz A, Schwartz T, Hehnke U, Kaffarnik H. Multicenter comparison of micronized fenofibrate and simvastatin in patients with primary type IIA or IIB hyperlipoproteinemia. J Cardiovasc Pharmacol. 1996;27(4):563-70. (Pubitemid 26107146)
36. Md S, Haque S, Sahni JK, Baboota S, Ali J. New non-oral drug delivery systems for Parkinson's disease treatment. Expert Opin Drug Deliv. 2011;8(3):359-74.
37. Di Stefano A, Sozio P, Iannitelli A, Cerasa LS. New drug delivery strategies for improved Parkinson's disease therapy. Expert Opin Drug Deliv. 2009;6(4):389-404.
38. Llorca P-M. Discussion of prevalence and management of discomfort when swallowing pills: orodispersible tablets expand treatment options in patients with depression. Ther Deliv. 2011;2(5):611-22.
39. Sanford M, Scott LJ. Spotlight on rotigotine transdermal patch in Parkinson's disease. Drugs Aging. 2011;28(12):1015-7.
40. Schnitzler A, Leffers KW, Hack HJ. High compliance with rotigotine transdermal patch in the treatment of idiopathic Parkinson's disease. Parkinsonism Relat Disord. 2010;16(8):513-6.
41. Lau HS, de Boer A, Beuning KS, Porsius A. Validation of pharmacy records in drug exposure assessment. J Clin Epidemiol. 1997;50(5):619-25. (Pubitemid 27270212)
42. Salat-Foix D, Suchowersky O. The management of gastrointestinal symptoms in Parkinson's disease. Expert Rev Neurother. 2012;12(2):239-48.
43. Simpson SH, Eurich DT, Majumdar SR, Padwal RS, Tsuyuki RT, Varney J, et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ. 2006;333:15-20.